Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.

Gao, Ruo-Lin; Song, Jun; Sun, Li; Wu, Zhi-Xuan; Yi, Xiao-Fang; Zhang, Shu-Ling; Huang, Le-Tian; Ma, Jie-Tao; Han, Cheng-Bo

Gao, Ruo-Lin; Song, Jun; Sun, Li; Wu, Zhi-Xuan; Yi, Xiao-Fang; Zhang, Shu-Ling; Huang, Le-Tian; Ma, Jie-Tao; Han, Cheng-Bo.

Afiliación

Gao RL; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Song J; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Sun L; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Wu ZX; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Yi XF; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Zhang SL; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Huang LT; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Ma JT; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Han CB; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.

Front Pharmacol ; 13: 920165, 2022.

Article en En | MEDLINE | ID: mdl-36034821

Palabras clave

angiogenesis inhibitors; chemotherapy; combination therapy; immunotherapy; non-small cell lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google